Article info
PDFOriginal research
Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non–small-cell lung cancer in China
- Correspondence to Mrs Yuan Jiang; jy_0609{at}163.com
Citation
Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non–small-cell lung cancer in China
Publication history
- Received January 12, 2020
- Revised June 8, 2020
- Accepted June 23, 2020
- First published July 31, 2020.
Online issue publication
October 18, 2023
Article Versions
- Previous version (22 April 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ.